Navigation Links
Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma
Date:6/2/2011

EXTON, Pa., June 2, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, phase II study of MORAb-004 for the treatment of metastatic melanoma. The study will evaluate MORAb-004, a potentially first-in-class monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1), as a single agent therapy comparing its safety and therapeutic activity at two dosages.

The trial is designed as an open-label study to assess the efficacy of single agent MORAb-004 at one of two doses as determined by progression-free survival in patients with metastatic melanoma. Secondary objectives include assessment of an overall survival benefit, identification of an optimal dose, identification of biomarkers to predict efficacy, and safety of single agent MORAb-004. The patient population includes individuals with metastatic melanoma who have received at least one previous drug regimen.  It is estimated that nearly all metastatic melanoma tumors are endosialin/TEM-1 positive.(1)

Morphotek expects to enroll up to 80 patients in this study, which is being conducted at clinical centers in the United States, Europe and Australia.  As part of the trial, patient tumors will be tested for endosialin/TEM-1 and/or proteins within its pathway to determine if the pattern of expression relates to or determines clinical effect.

"We are excited to have initiated this phase II study of MORAb-004 in melanoma," stated Christina Coughlin, M.D., Ph.D. Senior Director of Clinical Development at Morphotek. "New agents are needed for the treatment of metastatic melanoma which remains an area of significant unmet medical need in the field of oncology. We are pleased to have the opportunity to collaborate with several of the world's experts in this disease setting."

MORAb-004 is a humanized monoclonal antibody specific for endosialin/TEM-1 protein.  The target is found t
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morphotek®, Inc. Receives Beacon Award From CancerCare
2. Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues
3. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
4. Regal One Announces Dividend of Rampart Detection Systems Common Stock
5. PharmaNet Announces Tender Offer and Consent Solicitation
6. Biomatrica Announces the Appointment of Dr. James A. Robb as a Member of the Scientific Advisory Board
7. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
8. WaferGen Announces $30 Million Financing
9. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
10. Vermillion Announces Notice of Allowance for Alzheimer Patent
11. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Crystal Diagnostics (CDx) Xpress System, ... has received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing ... collectively referred to as STEC or the “Big-6”) as well ... unit (cfu) per 325 g of raw ground beef and ...
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... the leading,management consulting firm specializing in the pharmaceutical ... practice,will be taking a leadership role at the ... by the Center for Business Intelligence,(CBI). The conference ... Crown Plaza,Valley Forge in King of Prussia, Pennsylvania. ...
... (Nasdaq:,CPHD) will present at the William Blair & ... at 10:40 a.m. ET at the New York ... Financial Officer and Dr.,David Persing, Cepheid,s Chief Medical ... The webcast, along with accompanying presentation slides, may ...
... The Netherlands and LONDON, September 26 ,Nobilon International ... business,unit of Akzo Nobel, and Protherics PLC, the ... today announced that Nobilon,has licensed Protherics, CoVaccine HT(TM) ... influenza vaccines in elderly people. More than ...
Cached Biology Technology:Campbell Alliance Managed Markets Practice to Take Leadership Role at CBI's Formulary and Reimbursement Conference 2Campbell Alliance Managed Markets Practice to Take Leadership Role at CBI's Formulary and Reimbursement Conference 3Cepheid to Present at William Blair Small-Cap Growth Stock Conference 2Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 2Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 3
(Date:1/22/2015)... NXTD and NXTDW) a biometric authentication company focused on ... Wocket™ smart wallet at CES 2015 in Las Vegas ... the "11 Hot Products at CES" in a review published in Wired.com, ... Newseveryday.com and "The top 10 gadgets from CES 2015" by Danny ...
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... in biomechanics and physiology from six universities, led ... of Technologys Media Lab, refute scientific claims that ... South African bilateral amputee track athlete, provide him ... Their conclusions were based on data collected at ...
... has long been a concern for environmental scientists and ... excessive reactive nitrogen in the environment is little-known beyond ... the element cycles through the environment and negatively alters ... Two new papers by leading environmental scientists bring ...
... NY) Contrary to long-held assumptions, high-salt diets ... to investigators from the Albert Einstein College of ... after examining dietary intake among a nationally representative ... researchers actually observed a significantly increased risk of ...
Cached Biology News:Breaking news: Study revives Olympic prospects for amputee sprinter 2Breaking news: Study revives Olympic prospects for amputee sprinter 3Addressing the 'nitrogen cascade' 2Addressing the 'nitrogen cascade' 3New study casts further doubt on risk of death from higher salt intake 2